-

SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Class Action Against DocuSign, Inc. (DOCU)

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased DocuSign, Inc. (NASDAQ: DOCU) securities between March 27, 2020 and December 2, 2021. The complaint alleges violations of the Securities Exchange Act of 1934. DocuSign offers the Agreement Cloud, a cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device.

If you suffered a loss due to DocuSign Inc.'s misconduct, click here.

DocuSign, Inc. (DOCU) Made Material Misstatements Regarding its Business Prospects

According to the complaint, during the class period, defendants failed to disclose the role the COVID-19 pandemic had on its growth, including the positive impact on DocuSign's business. Defendants also downplayed the impact that a 'return to normal' would have on the Company's growth and business.

On December 2, 2021, DocuSign held an earnings conference call for its third quarter fiscal year 2022, revealing that its anticipated growth for the fourth quarter 2022 would be lower than expected. The Company explained that the growth boost from the COVID-19 pandemic had deteriorated earlier than expected. In a press release issued the same day, DocuSign provided guidance for the fourth quarter fiscal year 2022. The guidance provided midpoint revenue guidance of $560 million, missing analysts' consensus estimates of $573.8 million and a billing guidance of $653 million, missing consensus estimates of $704.5 million. On this news, DocuSign's stock price plummeted $98.73 per share, or over 42%, to close at $135.09 per share on December 3, 2021.

If you purchased shares of DocuSign, Inc. (DOCU) between March 27, 2020 and December 2, 2021, you have until February 22, 2022, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against DocuSign, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom